Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Aditi Saha et al.|Haematologica|2024Cited by 6
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Jennifer Santos, Jason T. Romancik, Loretta J. Nastoupil et al.|UNC Libraries|2024Cited by 0